CA2380355A1 - Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci - Google Patents

Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci Download PDF

Info

Publication number
CA2380355A1
CA2380355A1 CA002380355A CA2380355A CA2380355A1 CA 2380355 A1 CA2380355 A1 CA 2380355A1 CA 002380355 A CA002380355 A CA 002380355A CA 2380355 A CA2380355 A CA 2380355A CA 2380355 A1 CA2380355 A1 CA 2380355A1
Authority
CA
Canada
Prior art keywords
seq
polypeptide
acid sequence
pro
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002380355A
Other languages
English (en)
Inventor
Dan L. Eaton
Ellen Filvaroff
Mary E. Gerritsen
Audrey Goddard
Paul J. Godowski
Christopher J. Grimaldi
Austin L. Gurney
Colin K. Watanabe
William I. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/020111 external-priority patent/WO2000012708A2/fr
Priority claimed from PCT/US1999/021090 external-priority patent/WO2000015796A2/fr
Priority claimed from PCT/US2000/004342 external-priority patent/WO2000078961A1/fr
Priority claimed from PCT/US2000/004341 external-priority patent/WO2000053756A2/fr
Priority claimed from PCT/US2000/004414 external-priority patent/WO2001004311A1/fr
Priority claimed from PCT/US2000/005601 external-priority patent/WO2000056889A2/fr
Priority claimed from PCT/US2000/008439 external-priority patent/WO2000073454A1/fr
Priority claimed from PCT/US2000/014042 external-priority patent/WO2000077037A2/fr
Priority to CA002645727A priority Critical patent/CA2645727A1/fr
Priority to CA002481788A priority patent/CA2481788A1/fr
Priority to CA002481691A priority patent/CA2481691A1/fr
Priority to CA002481756A priority patent/CA2481756A1/fr
Priority to CA002481685A priority patent/CA2481685A1/fr
Priority to CA2481731A priority patent/CA2481731C/fr
Application filed by Individual filed Critical Individual
Publication of CA2380355A1 publication Critical patent/CA2380355A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Abstract

L'invention concerne des nouveaux polypeptides et des molécules d'acides nucléiques codant pour lesdits polypeptides. L'invention porte également sur des vecteurs et des cellules hôtes comprenant lesdites séquences nucléotidiques, sur des molécules de polypeptides chimères comprenant les polypeptides de l'invention fusionnés à des séquences polypeptidiques hétérologues, sur des anticorps se liant aux polypeptides de l'invention et sur des procédés de production des polypeptides de l'invention.
CA002380355A 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci Abandoned CA2380355A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA2481731A CA2481731C (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
CA002481685A CA2481685A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
CA002481756A CA2481756A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
CA002481691A CA2481691A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
CA002645727A CA2645727A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
CA002481788A CA2481788A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci

Applications Claiming Priority (31)

Application Number Priority Date Filing Date Title
PCT/US1999/020111 WO2000012708A2 (fr) 1998-09-01 1999-09-01 Nouveaux pro-polypeptides et sequences correspondantes
USPCT/US99/20111 1999-09-01
USPCT/US99/21090 1999-09-15
PCT/US1999/021090 WO2000015796A2 (fr) 1998-09-16 1999-09-15 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
US16949599P 1999-12-07 1999-12-07
US60/169,495 1999-12-07
US17026299P 1999-12-09 1999-12-09
US60/170,262 1999-12-09
US17548100P 2000-01-11 2000-01-11
US60/175,481 2000-01-11
PCT/US2000/004341 WO2000053756A2 (fr) 1999-03-08 2000-02-18 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
USPCT/US00/04341 2000-02-18
PCT/US2000/004342 WO2000078961A1 (fr) 1999-06-23 2000-02-18 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
USPCT/US00/04342 2000-02-18
PCT/US2000/004414 WO2001004311A1 (fr) 1999-07-07 2000-02-22 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
USPCT/US00/04414 2000-02-22
USPCT/US00/05601 2000-03-01
PCT/US2000/005601 WO2000056889A2 (fr) 1999-03-23 2000-03-01 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
US18720200P 2000-03-03 2000-03-03
US60/187,202 2000-03-03
US19100700P 2000-03-21 2000-03-21
US60/191,007 2000-03-21
USPCT/US00/08439 2000-03-30
PCT/US2000/008439 WO2000073454A1 (fr) 1999-06-02 2000-03-30 Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci
US19939700P 2000-04-25 2000-04-25
US60/199,397 2000-04-25
USPCT/US00/14042 2000-05-22
PCT/US2000/014042 WO2000077037A2 (fr) 1999-06-15 2000-05-22 Polypeptides secretes et transmembranaires et acides nucleiques les codant
US20983200P 2000-06-05 2000-06-05
US60/209,832 2000-06-05
PCT/US2000/023328 WO2001016318A2 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci

Related Child Applications (6)

Application Number Title Priority Date Filing Date
CA002481685A Division CA2481685A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
CA2481731A Division CA2481731C (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
CA002481788A Division CA2481788A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
CA002481691A Division CA2481691A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
CA002481756A Division CA2481756A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
CA002645727A Division CA2645727A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci

Publications (1)

Publication Number Publication Date
CA2380355A1 true CA2380355A1 (fr) 2001-03-08

Family

ID=40299613

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002380355A Abandoned CA2380355A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci

Country Status (5)

Country Link
EP (1) EP1208202A2 (fr)
JP (8) JP3951035B2 (fr)
AU (1) AU7573000A (fr)
CA (1) CA2380355A1 (fr)
WO (1) WO2001016318A2 (fr)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7057017B2 (en) 1997-04-16 2006-06-06 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
US20030130182A1 (en) * 1997-11-05 2003-07-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6562578B1 (en) 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
NZ505881A (en) 1998-01-09 2003-05-30 Immunex Corp IL-1 delta DNA and polypeptides
US7446181B2 (en) 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
ATE365800T1 (de) 1998-05-15 2007-07-15 Genentech Inc Therapeutische verwendungen von il-17 homologe polypeptide
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US7291712B2 (en) 1998-06-25 2007-11-06 Genentech, Inc. Interleukin-8 homologous polypeptides and therapeutic uses thereof
CA2341326A1 (fr) * 1998-09-03 2000-03-16 Takeda Chemical Industries, Ltd. Nouvelle proteine et son procede de production
US7244428B2 (en) * 1998-09-10 2007-07-17 Genentech, Inc. PRO1357 antibodies
US7244817B2 (en) * 1998-09-10 2007-07-17 Genentech, Inc. Pro1357 polypeptide
US6344541B1 (en) 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
US6962980B2 (en) 1999-09-24 2005-11-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6468546B1 (en) 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
AU2007216683B2 (en) * 1998-12-17 2011-07-14 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
US6858710B2 (en) 1998-12-17 2005-02-22 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6699664B1 (en) 1998-12-17 2004-03-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US7888477B2 (en) 1998-12-17 2011-02-15 Corixa Corporation Ovarian cancer-associated antibodies and kits
US20030190669A1 (en) * 1998-12-30 2003-10-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
CA2386141C (fr) * 1999-09-29 2012-10-23 Teijin Limited Polypeptide inedit et gene le codant
AU1437901A (en) * 1999-10-29 2001-05-14 Human Genome Sciences, Inc. 26 human secreted proteins
WO2001040467A1 (fr) 1999-12-03 2001-06-07 Zymogenetics, Inc. Recepteur de cytokine humaine
WO2001046419A2 (fr) * 1999-12-23 2001-06-28 Schering Corporation Proteines mammaliennnes, reactifs et procedes associes
US20030170823A1 (en) 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP1897946B1 (fr) * 1999-12-23 2012-07-11 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
EP1261639A2 (fr) * 2000-01-19 2002-12-04 Amgen Inc. Peptide apparente a la chondromoduline-i
AU2001255168A1 (en) * 2000-03-03 2001-09-17 Genentech Inc. Compositions and methods for the treatment of immune related diseases
US7094566B2 (en) 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
WO2001074854A2 (fr) * 2000-03-31 2001-10-11 Millennium Pharmaceuticals, Inc. Le 32449, nouveau transporteur humain et ses utilisations
GB0009907D0 (en) * 2000-04-20 2000-06-07 Smithkline Beecham Biolog Novel compounds
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001268440A1 (en) * 2000-06-15 2002-01-08 Millennium Pharmaceuticals, Inc. 53320, a human acyltransferase and uses therefor
EP1294885A2 (fr) * 2000-06-30 2003-03-26 Amgen, Inc. Molecules de type b7 et utilisation de ces molecules
EP1736545A3 (fr) * 2000-08-08 2007-03-28 ZymoGenetics, Inc. Récepteurs de cytokines zcytor 11 solubles
DE60123998T2 (de) 2000-08-08 2007-09-06 Zymogenetics, Inc., Seattle Lösliche zcyctor 11 cytokinrezeptoren
US20040171109A1 (en) * 2000-11-10 2004-09-02 Dominik Haudenschild IL-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage
EP1873245A1 (fr) * 2001-02-28 2008-01-02 Genentech, Inc. Polypeptides homologue à l'interleukine-8 et utilisations thérapeutiques correspondantes
AU2002252460A1 (en) 2001-03-27 2002-10-08 Zymogenetics, Inc. Human cytokine receptor
WO2003008589A1 (fr) * 2001-07-18 2003-01-30 Asahi Kasei Kabushiki Kaisha Elk1 gene associe a la phosphorylation
US20030023042A1 (en) * 2001-12-06 2003-01-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
IL164181A0 (en) 2002-03-22 2005-12-18 Zymogenetics Inc Anti-il-tif antibodies and methods of using in inflammation
EP2305710A3 (fr) 2002-06-03 2013-05-29 Genentech, Inc. Bibliothèques de phages et anticorps synthétiques
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP2311870A1 (fr) * 2002-11-26 2011-04-20 Genentech, Inc. Compositions et procédés pour le traitement de maladies liées au système immunitaire
KR20050105459A (ko) * 2003-02-05 2005-11-04 제넨테크, 인크. 종양 세포에 의해 차별적으로 발현되는 세포성폴리펩티드의 동정
US7312197B2 (en) 2003-02-24 2007-12-25 University Of Maryland, Baltimore Method of modifying glucose activity using polypeptides selectively expressed in fat tissue
DE602004028347D1 (de) 2003-03-24 2010-09-09 Zymogenetics Inc Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
EP2277908A3 (fr) 2003-07-08 2011-12-14 Genentech, Inc. Polypeptides hétérologues IL-14A/F, anticorps et utilisations thérapeutiques associées
ES2697327T3 (es) 2003-11-06 2019-01-23 Seattle Genetics Inc Compuesto intermedio para la preparación de conjugados que comprenden derivados de auristatina y un enlazador
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
WO2005079566A2 (fr) * 2004-02-12 2005-09-01 Lexicon Genetics Incorporated Nouvelles disruptions geniques, compositions et procedes associes
DE102004024617A1 (de) * 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
MXPA06014065A (es) 2004-06-01 2007-01-31 Genentech Inc Conjugados de droga-anticuerpo y metodos.
EP1786837B1 (fr) 2004-08-04 2013-05-01 Amgen Inc., Anticorps contre dkk-1
JP4948413B2 (ja) 2004-09-23 2012-06-06 ジェネンテック， インコーポレイテッド システイン操作抗体および結合体
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP1812476B1 (fr) 2004-10-22 2010-07-21 ZymoGenetics, Inc. Anticorps anti-il-22ra et partenaires de liaison et methodes d'utilisation de ces anticorps et de ces partenaires de liaison pour le traitement de maladies inflammatoires
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
US7737259B2 (en) 2005-12-02 2010-06-15 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling
WO2008042826A2 (fr) 2006-09-29 2008-04-10 University Of Maryland, Baltimore Utilisation d'omentine1 et d'omentine pour le diagnostic et le traitement de maladies
AU2009245440C1 (en) 2008-05-05 2013-03-14 Novimmune Sa Anti-IL-17A/IL-17F cross-reactive antibodies and methods of use thereof
EP2427203B1 (fr) 2009-05-05 2018-10-17 Novimmune S.A. Anticorps anti-il-17f et leurs utilisation
JP2013504585A (ja) 2009-09-09 2013-02-07 セントローズ， エルエルシー 細胞外標的化薬物複合体
US20130028917A1 (en) 2010-04-15 2013-01-31 Spirogen Developments Sàrl Pyrrolobenzodiazepines and conjugates thereof
RU2626537C2 (ru) 2010-06-08 2017-07-28 Дженентек, Инк. Полученные с помощью генной инженерии антитела с цистеиновыми заменами и их конъюгаты
US20120121615A1 (en) 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
MX2013013054A (es) 2011-05-12 2014-02-20 Genentech Inc Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura.
EA026827B1 (ru) 2011-10-14 2017-05-31 Медимьюн Лимитед Пирролбензодиазепины и их конъюгаты
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
WO2013174404A1 (fr) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
PT2906253T (pt) 2012-10-12 2018-11-05 Medimmune Ltd Conjugados de anticorpo anti-psma de pirrolobenzodiazepina
DK2906296T3 (en) 2012-10-12 2018-05-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
SI2766048T1 (sl) 2012-10-12 2015-03-31 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
WO2014057120A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués anticorps - pyrrolobenzodiazépine
WO2014057114A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués pyrrolobenzodiazepine-anticorps anti-psma
NZ707490A (en) 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
WO2014057117A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués pyrrolobenzodiazépine-anticorps
KR102643443B1 (ko) 2012-11-13 2024-03-06 비온테크 에스이 클라우딘 발현 암 질환의 치료제
CA2894961C (fr) 2012-12-21 2020-09-15 Spirogen Sarl Pyrrolobenzodiazepines et conjugues associes
CN105246894A (zh) 2012-12-21 2016-01-13 斯皮罗根有限公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
WO2014127785A1 (fr) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
EP2968585B1 (fr) 2013-03-13 2018-07-18 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
EA027910B1 (ru) 2013-03-13 2017-09-29 Медимьюн Лимитед Пирролобензодиазепины и их конъюгаты
EP2968594B1 (fr) 2013-03-13 2019-04-24 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
WO2014146672A1 (fr) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer
CA2918139A1 (fr) 2013-08-12 2015-02-19 Genentech, Inc. Conjugues anticorps-medicament dimerique 1-(chloromethyl)-2,3-dihydro-1 h-benzo [e]indole, et methodes d'utilisation et de traitement
WO2015052532A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépines
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052534A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépine
WO2015052535A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépine
KR102354207B1 (ko) 2013-12-16 2022-01-20 제넨테크, 인크. 펩티드모방체 화합물 및 그의 항체-약물 접합체
KR20160092024A (ko) 2013-12-16 2016-08-03 제넨테크, 인크. 1-(클로로메틸)-2,3-디히드로-1H-벤조[e]인돌 이량체 항체-약물 접합체 화합물, 및 사용 및 치료 방법
EA201691023A1 (ru) 2013-12-16 2016-10-31 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
EP3193940A1 (fr) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
KR20170052600A (ko) 2014-09-12 2017-05-12 제넨테크, 인크. 시스테인 가공된 항체 및 콘주게이트
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3194400A1 (fr) 2014-09-17 2017-07-26 Genentech, Inc. Pyrrolobenzodiazépines et conjugués à base de disulfure d'anticorps associés
CA2968447A1 (fr) 2014-11-25 2016-06-02 Adc Therapeutics Sa Conjugues anticorps-pyrrolobenzodiazepine
JP6752204B2 (ja) 2014-12-03 2020-09-09 ジェネンテック， インコーポレイテッド 四級アミン化合物及びその抗体−薬物コンジュゲート
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
WO2017205741A1 (fr) 2016-05-27 2017-11-30 Genentech, Inc. Procédé bioanalytique pour la caractérisation de conjugués anticorps-médicament spécifiques d'un site
WO2017214024A1 (fr) 2016-06-06 2017-12-14 Genentech, Inc. Médicaments conjugués d'anticorps silvestrol et procédés d'utilisation
WO2018031662A1 (fr) 2016-08-11 2018-02-15 Genentech, Inc. Promédicaments de pyrrolobenzodiazépine et conjugués d'anticorps de ceux-ci
EP3522933B1 (fr) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Procédés de préparation de conjugués anticorps-médicament
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CN110582505B (zh) 2017-04-18 2021-04-02 免疫医疗有限公司 吡咯并苯并二氮杂*缀合物
EP3612234B1 (fr) 2017-04-20 2024-03-13 ADC Therapeutics SA Polythérapie avec un conjugué anticorps anti-axl-médicament
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
SI3668874T1 (sl) 2017-08-18 2022-04-29 Medimmune Limited Pirolobenzodiazepinski konjugati
BR112020004307A2 (pt) 2017-09-20 2020-11-10 Ph Pharma Co., Ltd. análogos de tailanestatina
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
AU2019365238A1 (en) 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
JP2022513198A (ja) 2018-12-10 2022-02-07 ジェネンテック， インコーポレイテッド Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
EP0874902A2 (fr) * 1996-01-11 1998-11-04 Corixa Corporation Compositions et procedes pour le traitement et le diagnostic du cancer du sein
US5824504A (en) * 1996-09-26 1998-10-20 Elshourbagy; Nabil A. Human 7-transmembrane receptor and DNA
WO1999063088A2 (fr) * 1998-06-02 1999-12-09 Genentech, Inc. Proteines membranaires et acides nucleiques codant ces proteines
CA2308768A1 (fr) * 1997-11-07 1999-05-20 Human Genome Sciences, Inc. 125 proteines secretees humaines
JP2001523453A (ja) * 1997-11-13 2001-11-27 ジェンセット 分泌タンパク質の伸長ｃＤＮＡ
AU2997299A (en) * 1998-03-11 1999-09-27 Genetics Institute Inc. Secreted proteins and polynucleotides encoding them
CN1158386C (zh) * 1998-04-29 2004-07-21 吉尼西斯研究及发展有限公司 从皮肤细胞中分离的多核苷酸及其使用方法
CA2383254A1 (fr) * 1999-06-02 2000-12-07 Genentech, Inc. Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci

Also Published As

Publication number Publication date
JP2005253469A (ja) 2005-09-22
JP2005224245A (ja) 2005-08-25
WO2001016318A3 (fr) 2001-11-29
EP1208202A2 (fr) 2002-05-29
WO2001016318A2 (fr) 2001-03-08
JP2009095345A (ja) 2009-05-07
JP2005261437A (ja) 2005-09-29
AU7573000A (en) 2001-03-26
JP2005270107A (ja) 2005-10-06
JP3951035B2 (ja) 2007-08-01
JP2005245460A (ja) 2005-09-15
JP2004507204A (ja) 2004-03-11
JP2005253468A (ja) 2005-09-22

Similar Documents

Publication Publication Date Title
US7189564B2 (en) PRO1335 nucleic acids
US7160985B2 (en) Pro180 polypeptide
CA2380355A1 (fr) Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
US7189815B2 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20080286821A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7319008B2 (en) Nucleic acid underexpressed in melanoma
US7351543B2 (en) Antibodies to a polypeptide encoded by a nucleic acid underexpressed in melanoma
US7300758B2 (en) Nucleic acid underexpressed in esophageal tumor
US20060160186A1 (en) Nucleic acid underexpressed in stomach tumor and lung tumor
CA2481731C (fr) Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
US20050059102A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7244817B2 (en) Pro1357 polypeptide
US7288384B2 (en) Antibodies to polypeptides encoded by a nucleic acid underexpressed in esophageal tumor
US7423127B2 (en) Antibodies to a polypeptide encoded by a nucleic acid overexpressed in melanoma
CA2645727A1 (fr) Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
EP1623991A2 (fr) Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead